tbuckley/cabot-search huggingface dataset:
Abstract 20985: CHA2DS2-VASc Score Predicts Risk of Incident Stroke in Patients Without Atrial Fibrillation/ Flutter in a Referral Population
Authors: Nasir Hussain, Bernard J Gersh, Stephen L Kopecky, Randal J Thomas, Thomas G Allison
Journal: Circulation (2017)

Background: CHA2DS2-VASc score has been shown to predict occurrences of incident stroke in patients with history of atrial fibrillation (A-Fib)/ Flutter. However, data on whether if CHA2DS2-VASc score would predict incidence of stroke in patients without A-Fib/ Flutter is less clear. Methods: From 1993 through 2010, all patients undergoing a clinically indicated treadmill exercise test (TMET) at the Mayo Clinic, Rochester, MN were identified (N= 76,857). From this, Olmsted and neighboring counties residents were selected (N=14,095). From this, patients with age &lt;18 years; prior history of valvular heart disease or A-Fib/ Flutter were excluded. Patient undergoing only Bruce or accelerated Naughton protocols on TMET were considered. Patients were stratified into 4 groups at baseline based on CHA2DS2-VASc score as determined at the time of TMET; group-0 score=0; group-I=1; group-2=2; group-3≥3. Patients were prospectively followed from the date of TMET until end of January 2016 for occurrence of incident stroke (ischemic and hemorrhagic). Stroke diagnosis was ascertained through retrospective chart review. Traumatic intracranial bleed was not considered. Proportional hazard regression modeling was done to assess relationship of CHA2DS2-VASc score with the stroke outcome while adjusting for METs achieved, sex, obesity, smoking status, and other relevant risk factors. Results: Final study population comprised of 12,624 patients with female comprising 37% of the cohort. Mean age in our study group was 52.2 ± 12.8 years. During an overall median follow-up of 14 (8 to 17) years, 1,255 (9.9%) patients developed incident stroke. While using CHA2DS2-VASc group-3 as referent, patients in CHA2DS2-VASc group-0 [0.18(0.14-0.23, p&lt;.001)], group-1[0.33 (0.28-0.39, p&lt;.001)], and group-2 [0.50 (0.43-0.58, p&lt;.001)] were at significantly lower risk of developing stroke. Each increase of one point on the CHA2DS2-VASc scale was associated with a 51% [1.51(1.45-1.58, p&lt;.001)] increase in incidence of stroke. Conclusion: CHA2DS2-VASc score predicts incidence of stroke in patients without history of A-Fib/ Flutter.
Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod.
Authors: Christina Y. Chia, B. Douglas Smith, Yvette Kasamon, Carole B. Miller, Mary E. Brummet, Lora Bankova, Jeanne Kowalski, Barbara Biedrzycki, Kristen Hege, Lisa A. Beck, Hyam Levitsky
Journal: Blood (2005)
von Willebrand Factor/Factor VIII Concentrate (Humate-P®) Is Safe and Effective in the Prevention of Perioperative Bleeding in Patients with Very Low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo).
Authors: Joan Cox Gill, Cindy A. Leissinger, Jorge DiPaola, Jonathan Bernstein, Margaret V. Ragni, Rinah Shopnick, Leonard A. Valentino, Sigurd Knaub, Carl Friedman
Journal: Blood (2006)
Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).
Authors: Partow Kebriaei, Rima M. Saliba, Carrie Ma, Cindy Ippoliti, Daniel R. Couriel, Marcos de Lima, Sergio Giralt, Muzaffar H. Qazilbash, James L. Gajewski, Chul S. Ha, Richard E. Champlin, Issa F. Khouri
Journal: Blood (2005)
Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations
Authors: Martin C Müller, Jorge Cortes, Dong-Wook Kim, Brian J. Druker, Philipp Erben, Ricardo Pasquini, Timothy P Hughes, Yousif Matloub, Lynn Ploughman, Andreas Hochhaus
Journal: Blood (2008)
Early Myeloablative Allogeneic Stem Cell Transplantation during High-Dose Cytarabin Induced Cytopenia in Patients with Refractory or Relapsed Myeloid Leukemias.
Authors: Thorsten T. Graef, Frank F. Neumann, Roland R. Fenk, Mustafa M. Kondakci, Lailani L. Ruf, Ulrich U. Steidl, Rainer R. Haas, Guido G. Kobbe
Journal: Blood (2004)
Superior Long-term Survival for Simultaneous Pancreas-Kidney Transplantation as Renal Replacement Therapy: 30-Year Follow-up of a Nationwide Cohort
Authors: Kevin Esmeijer, Ellen K. Hoogeveen, Paul J.M. van den Boog, Cynthia Konijn, Marko J.K. Mallat, Andre G. Baranski, Olaf M. Dekkers, Johan W. de Fijter, Frederike J. Bemelman, Azam Nurmohamed, Aiko P. de Vries, Maarten H.L. Christiaans, Luuk B. Hilbrands, Stefan P. Berger, Dennis A. Hesselink, Arjan D. van Zuilen
Journal: Diabetes Care (2019)

In patients with type 1 diabetes and end-stage renal disease, it is controversial whether a simultaneous pancreas-kidney (SPK) transplantation improves survival compared with kidney transplantation alone. We compared long-term survival in SPK and living- or deceased-donor kidney transplant recipients.We included all 2,796 patients with type 1 diabetes in the Netherlands who started renal replacement therapy between 1986 and 2016. We used multivariable Cox regression analyses adjusted for recipient age and sex, dialysis modality and vintage, transplantation era, and donor age to compare all-cause mortality between deceased- or living-donor kidney and SPK transplant recipients. Separately, we analyzed mortality between regions where SPK transplant was the preferred intervention (80% SPK) versus regions where a kidney transplant alone was favored (30% SPK).Of 996 transplanted patients, 42%, 16%, and 42% received a deceased- or living-donor kidney or SPK transplant, respectively. Mean (SD) age at transplantation was 50 (11), 48 (11), and 42 (8) years, respectively. Median (95% CI) survival time was 7.3 (6.2; 8.3), 10.5 (7.2; 13.7), and 16.5 (15.1; 17.9) years, respectively. SPK recipients with a functioning pancreas graft at 1 year (91%) had the highest survival (median 17.4 years). Compared with deceased-donor kidney transplant recipients, adjusted hazard ratios (95% CI) for 10- and 20-year all-cause mortality were 0.79 (0.49; 1.29) and 0.98 (0.69; 1.39) for living-donor kidney and 0.67 (0.46; 0.98) and 0.79 (0.60; 1.05) for SPK recipients, respectively. A treatment strategy favoring SPK over kidney transplantation alone showed 10- and 20-year mortality hazard ratios of 0.56 (0.40; 0.78) and 0.69 (0.52; 0.90), respectively.Compared with living- or deceased-donor kidney transplantation, SPK transplant was associated with improved patient survival, especially in recipients with a long-term functioning pancreatic graft, and resulted in an almost twofold lower 10-year mortality rate.
How to recognise sudden cardiac arrest on the pitch
Authors: Jelle SY de Jong, Harald T Jorstad, Roland D Thijs, Ruud W Koster, Wouter Wieling
Journal: British Journal of Sports Medicine (2019)

Sudden cardiac arrest (SCA), which occurs at a rate of about 1 in ~50 000 athlete years, is the most common cause of death in exercising young athletes.1 SCA is most frequently caused by lethal cardiac arrhythmias—that is, ventricular fibrillation (VF). If clinicians recognise key features of SCA early and accurately, they can immediately begin cardiopulmonary resuscitation (CPR) and use an automated external defibrillator (AED) as needed.2 This review aims to (1) assist health professionals recognise the signs (and avoid common pitfalls) of SCA and (2) emphasise best practice responder strategies for SCA on the pitch.

Miklos Feher, a striker for Benfica, suffered a SCA on 25 January 2004. The event can be viewed at: https://youtu.be/T7-kKy_XDQU. The underlying cause of death was later reported to be VF in a patient with hypertrophic cardiomyopathy.

How can clinicians and sports professionals rapidly recognise SCA on the field of play? Recognising SCA on the pitch can be challenging due to the sports setting, other mimicking causes and the rapid onset of signs following cerebral hypoperfusion. To prevent death or serious sequelae, it is key that clinicians recognise SCA immediately and start adequate management (ie, CPR and defibrillation).

Figure 1 is a schematic of SCA from time T=0–60 s with corresponding signs, ECG, blood pressure tracing and breathing pattern. Prolonged, sudden cerebral hypoperfusion causes a typical …
Cochrane launches new research field to tackle overdiagnosis and medical excess
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The medical publisher Cochrane has launched a new research field, Cochrane Sustainable Healthcare, to advocate and promote the use of evidence to ensure a more sustainable approach to healthcare.1

The new field will bring together patients, healthcare professionals, researchers, policy makers, and carers to tackle overdiagnosis and medical excess. It is one of 13 Cochrane fields, which aim to foster, support, and coordinate …
A Randomized Trial Comparing the Effectiveness of Peripheral Blood Stem Cell Mobilization with Chemotherapy and Early vs Delayed Initiation of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Lymphoma and Multiple Myeloma.
Authors: Isabelle A. Bence-Bruckler, Sheryl McDiarmid, Harold L. Atkins, Mitchell Sabloff, Isabelle Gauthier, Lothar B. Huebsch
Journal: Blood (2005)
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Authors: Daniel O. Persky, Hongli Li, Deborah M. Stephens, Steven I Park, Nancy L. Bartlett, Lode J. Swinnen, Paul M. Barr, Jerome D. Winegarden, Louis S. Constine, Thomas J. Fitzgerald, John P. Leonard, Brad S. Kahl, Michael L. Leblanc, Joo Y. Song, Richard I. Fisher, Lisa M. Rimsza, Sonali M. Smith, Jonathan W. Friedberg
Journal: Blood (2019)
Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children
Authors: Larisa Shelikhova, Rimma Khismatullina, Michael Maschan, Alexey A. Maschan, Irina Kalinina, Elena Kurnikova, Yakov Muzalevsky, Alexey Kazachenok, Dmitriy Pershin, Alexander Popov, Galina Novichkova, Dmitriy Balashov, Daria Shasheleva, Svetlana Kashpor, Evgeny Gluhanyuk
Journal: Blood (2019)
Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML)
Authors: Fabio P.S. Santos, Hagop Kantarjian, Carmen Fava, Susan O’Brien, Guillermo Garcia-Manero, Steven Kornblau, Farhad Ravandi, William Wierda, Jorge Cortes
Journal: Blood (2008)
Altered Cellular Protein Levels of Tumor Suppressor Genes and Heat Shock Elements (TRAP1) Indicate Sensitivity to the Proteasome Inhibitor Bortezomib (Velcade®) in Mantle Cell Lymphoma.
Authors: Marc Weinkauf, Malte Rieken, Alessandro Pastore, Elena Hartmann, Andreas Rosenwald, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2005)
Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.
Authors: Pamala A. Jacobson, John Rogosheske, Kathleen Green, Claudio Brunstein, Juliet Barker, Jeff Miller, John Wagner, Philip McGlave, Ye Tan, Daniel Weisdorf
Journal: Blood (2005)
Viewing the Community-acquired Pneumonia Guidelines through an Antibiotic Stewardship Lens
Authors: Valeria Fabre, Emily S. Spivak, Sara C. Keller
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

suspected and radiographically confirmed CAP (1).It seems rational that in a patient with a high pretest probability for pneumonia, any biomarker (including PCT) that is not 100% accurate should not have a strong influence on treatment decisions.The advantage of using PCT for the management of patients with CAP, however, has been demonstrated for patients in whom a CAP diagnosis is unclear (e.g., patients with no infiltrate in chest X-ray) and for monitoring patients with CAP to decide whether to stop treatment early.Most trials that evaluated PCT for the management of CAP did not rely on the initial PCT level and instead focused on the kinetics of this blood marker to indicate that antibiotic treatment should be stopped early.The initial PCT level was found to be helpful in patients with a bronchitis-like illness and possible CAP but an ambiguous clinical presentation (2, 3).A recent meta-analysis of individual patient data that focused specifically on patients with respiratory infection and CAP who had participated in randomized trials showed that PCT is highly effective in reducing the duration of antibiotic treatment (4, 5).Specifically, the analysis included 6,708 patients from 26 eligible trials in 12 countries and found a 2.4-day reduction in antibiotic exposure (5.7 vs. 8.1 d [95% confidence interval (CI), -2.71 to -2.15]; P , 0.0001) and a reduction in antibiotic-related side effects (16% vs. 22%, adjusted odds ratio, 0.68 [95% CI, 0.57 to 0.82]; P , 0.0001).Importantly, when PCT was used to guide discontinuation of treatment, patients had significantly improved clinical outcomes (odds ratio for mortality, 0.83 [95% CI, 0.70-0.99];P = 0.037).Thus, there is strong clinical evidence that PCT is useful for evaluating patients with lower respiratory infection and ambiguous presentation and for stopping antibiotics early in patients with confirmed CAP.It is unfortunate that the updated guideline (1) focused on a clinical situation in which no biomarker would be expected to have a strong influence on treatment (i.e., patients with clinically suspected and radiographically confirmed CAP) and unfortunate that it did not include recommendations for using PCT in ambiguous clinical situations and for guiding treatment duration, both of which have a strong impact on antibiotic overuse and associated health risks.
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.
Authors: Denise Woo, Chris Jones, Monique Vanoli-Storz, Sabine Kohler, Sunil Reddy, Ranjana Advani, Richard Hoppe, Youn Kim
Journal: Blood (2007)
Interphase FISH Analysis Reveals High Frequence of Partial 6q Deletions in Adult Acute Lymphoblastic Leukemia (ALL) with Normal or Failed Karyotype.
Authors: Marco Mancini, Paola Gaspari, Daniela Scappaticci, Raffaella Isidori, Cristina Ariola, Loredana Elia, Fabrizio Pane, Francesco Fabbiano, Felicetto Ferrara, Andrea Camera, Caterina Musolino, Luciana Annino, Ruggero Mozzana, Nicola Cantore, Filippo Marmont, Robin Foà
Journal: Blood (2005)
Abstract 10616: Clinical Implication of Very Low Dose of Sacubitril/valsartan for Patients With Heart Failure With Reduced Ejection Fraction; Beyond PARADIGM-HF and PIONEER-HF Trial
Authors: Hyoeun Kim, Jaewon Oh, Jaehyung Ha, Kyeong-Hyeon Chun, Chan Joo Lee, Sungha Park, Sang-Hak Lee, Seok-Min Kang
Journal: Circulation (2019)

Background: Sacubitril/Valsartan (SV) has shown to be superior to the ACEi enalapril, reducing the risk of death and heart failure hospitalization in patients with heart failure with reduced ejecti...
Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model
Authors: Naoya Uchida, Linhong Li, Tina Nassehi, Morgan Yapundich, Jackson Gamer, Claire Drysdale, Juan J. Haro-Mora, Selami Demirci, Aylin Bonifacino, Allen Krouse, Nathaniel S. Linde, Cornell Allen, Suk See De Ravin, Robert E. Donahue, Harry L. Malech, Madhusudan Peshwa, John F. Tisdale
Journal: Blood (2019)
Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.
Authors: Natalie Callander, Jose L. Ochoa-Bayona, Lawrence Piro, Susan Guba, Gabriel Shapiro, Stephanie Williams, Ira Oliff, Howard Burris, Anneliese Jameson, Kiran Patel, Gail L. Brown, Stefan Faderl, Zeev Estrov, Peter Emanuel
Journal: Blood (2004)
Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin.
Authors: Walter P. Jeske, Jeanine M. Walenga, Paul D. Ackerman, Debra A. Hoppensteadt, Curtis Vandenberg, Rodger L. Bick, Jawed Fareed
Journal: Blood (2006)
Contribution of HLA Incompatibility on Clinical Outcomes of CBT in Patients with MDS Including Secondary AML in Japan: Multivariate Analysis Using Competing Risk Regression Model
Authors: Satoshi Takahashi, Takuhiro Yamaguchi, Maki Monna-Ooiwa, Shuichi Taniguchi, Hisashi Sakamaki, Takeshi Morii, Yoshihisa Nagatoshi, Nobuyuki Aotsuka, Shunichi Kato, Minoko Takanashi, Tokiko Nagamura, Hiroshi Azuma, Shunro Kai, Koji Kato, Shigetaka Asano
Journal: Blood (2008)
Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia
Authors: Yuki B. Werner, Bengt Hakanson, Jan Martinek, Alessandro Repici, Burkhard H.A. von Rahden, Albert J. Bredenoord, Raf Bisschops, Helmut Messmann, Marius C. Vollberg, Tania Noder, Jan F. Kersten, Oliver Mann, Jakob Izbicki, Alexander Pazdro, Uberto Fumagalli, Riccardo Rosati, Christoph-Thomas Germer, Marlies P. Schijven, Alice Emmermann, Daniel von Renteln, Paul Fockens, Guy Boeckxstaens, Thomas Rösch
Journal: New England Journal of Medicine (2019)

Pneumatic dilation and laparoscopic Heller’s myotomy (LHM) are established treatments for idiopathic achalasia. Peroral endoscopic myotomy (POEM) is a less invasive therapy with promising early study results.
Dynamically Crystalizing Liquid‐Crystal Elastomers for an Expandable Endplate‐Conforming Interbody Fusion Cage
Authors: Ross H. Volpe, Devesh Mistry, Vikas V. Patel, Ravi R. Patel, Christopher M. Yakacki
Journal: Advanced Healthcare Materials (2019)

Abstract Degenerative disc disease (DDD) is the leading cause of low back pain and radiating leg pain. DDD is commonly treated surgically using spinal fusion techniques, but in many cases failure occurs due to insufficient immobilization of the vertebrae during fusion. The fabrication and demonstration of a 3D‐printed semi‐crystalline liquid crystal elastomer (LCE) spinal fusion cage that addresses these challenges in particular subsidence are described. During implantation of the fusion cage, the LCE is rubbery and capable of deforming around and conforming to delicate anatomy. In the hours following implantation, the device crystallizes into a rigid, structural material with the modulus increasing tenfold from 8 to 80 MPa. In the crystalline regime, a 3D‐printed prototype device is capable of enduring 1 million cycles of physiologic compressive loading with minimal creep‐induced ratcheting. Effects of LCE molecular architecture on the rate and magnitude of modulus increase, material processability, and mechanical properties are explored. This fundamental characterization informs a proof‐of‐concept device—the first bulk 3D printed LCE demonstrated to date. Moreover, the novel deployment strategy represents an exciting new paradigm of spinal fusion cages, which addresses real clinical challenges in expandable interbody fusion cages.
Rac1, but Not Rac2, Mediates Osteoclast Gain-of-Function Induced by Nf1 Haploinsufficiency.
Authors: Shi Chen, Jincheng Yan, Yingze Zhang, Yan Li, Xiaohong Li, Jin Yuan, Selina Eskwick, Todd D. Nebesio, Alexander Robling, Rebecca J. Chan, FengChun Yang
Journal: Blood (2007)
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
Authors: Sharon A. Hunt, David W. Baker, Marshall H. Chin, Michael P. Cinquegrani, Arthur M. Feldmanmd, Gary S. Francis, Theodore G. Ganiats, Sidney Goldstein, Gabriel Gregoratos, Mariell L. Jessup, R. Joseph Noble, Milton Packer, Marc A. Silver, Lynne Warner Stevenson, Raymond J. Gibbons, Elliott M. Antman, Joseph S. Alpert, David P. Faxon, Valentin Fuster, Gabriel Gregoratos, Alice K. Jacobs, Loren F. Hiratzka, Richard O. Russell, Sidney C. Smith
Journal: Circulation (2001)
ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo
Authors: Pier Paolo Piccaluga, Maura Rossi, Aurora Esposito, Pier Luigi Tazzari, Francesca Ricci, Giordano Nicoletti, Lorena Landuzzi, Stefano Fanti, Valentina Ambrosini, Flavio Leoni, Paolo Mascagni, Anna Gazzola, Pier Luigi Lollini, Pier Luigi Zinzani, Stefano A. Pileri
Journal: Blood (2008)
Abstract 16033: Prolonged Use of Clopidogrel and Risk of Death, Myocardial Infarction, and Major Bleeding 5 Years after Coronary Stenting in VA Patients with Chronic Kidney Disease
Authors: Omar Siddiqi, David Faxon, Michael Gaziano, Melissa Young, Elizabeth Lawler, Scott Kinlay
Journal: Circulation (2012)

Current guidelines for drug-eluting (DES) and bare metal stents (BMS) include clopidogrel for up to one year after stenting. Patients with chronic kidney disease (CKD) have a higher risk of death, ...
Estimating the effect of the 2005 change in BCG policy in England: a retrospective cohort study, 2000 to 2015
Authors: Sam Abbott, Hannah Christensen, Nicky J. Welton, Ellen Brooks-Pollock
Journal: Eurosurveillance (2019)

Background In 2005 in England, universal Bacillus Calmette–Guérin (BCG) vaccination of school-age children was replaced by targeted BCG vaccination of high-risk neonates. Aim Estimate the impact of the 2005 change in BCG policy on tuberculosis (TB) incidence rates in England. Methods We conducted an observational study by combining notifications from the Enhanced Tuberculosis Surveillance system, with demographic data from the Labour Force Survey to construct retrospective cohorts relevant to both the universal and targeted vaccination between 1 January 2000 and 31 December 2010. We then estimated incidence rates over a 5-year follow-up period and used regression modelling to estimate the impact of the change in policy on TB. Results In the non-United Kingdom (UK) born, we found evidence for an association between a reduction in incidence rates and the change in BCG policy (school-age incidence rate ratio (IRR): 0.74; 95% credible interval (CrI): 0.61 to 0.88 and neonatal IRR: 0.62; 95%CrI: 0.44 to 0.88). We found some evidence that the change in policy was associated with an increase in incidence rates in the UK born school-age population (IRR: 1.08; 95%CrI: 0.97 to 1.19) and weaker evidence of an association with a reduction in incidence rates in UK born neonates (IRR: 0.96; 95%CrI: 0.82 to 1.14). Overall, we found that the change in policy was associated with directly preventing 385 (95%CrI: −105 to 881) cases. Conclusions Withdrawing universal vaccination at school age and targeting vaccination towards high-risk neonates was associated with reduced incidence of TB. This was largely driven by reductions in the non-UK born with cases increasing in the UK born.
Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage
Authors: A. Huttner, J. Bielicki, M.N. Clements, N. Frimodt-Møller, A.E. Muller, J.-P. Paccaud, J.W. Mouton
Journal: Clinical Microbiology and Infection (2019)
A Genomic and Proteomic Research for the Regulatory Networks of ATRA-Induced Differentiation of Acute Promyelocytic Leukemia Cells.
Authors: Qiu-Hua Huang, Qun-Ye Zhang, Shu-Hong Shen, Pei-Zheng Zheng, Jing Lu, Yi Jing, Ji Zhang, Kan-Kan Wang, Sai-Juan Chen, Zhu Chen
Journal: Blood (2004)